Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kuros Biosciences's Enterprise Value is CHF370.61 Mil.
Kuros Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-13.16 Mil. Therefore, Kuros Biosciences's EV-to-EBIT ratio for today is -28.16.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kuros Biosciences's Enterprise Value is CHF370.61 Mil.
Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-10.41 Mil. Therefore, Kuros Biosciences's EV-to-EBITDA ratio for today is -35.61.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kuros Biosciences's Enterprise Value is CHF370.61 Mil.
Kuros Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF33.56 Mil. Therefore, Kuros Biosciences's EV-to-Revenue ratio for today is 11.04.
Kuros Biosciences Enterprise Value Historical Data
The historical data trend for Kuros Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kuros Biosciences's Enterprise Value
For the Medical Devices subindustry, Kuros Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Enterprise Value falls into.
Kuros Biosciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Kuros Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (XSWX:KURN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Kuros Biosciences's current Enterprise Value is CHF370.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-13.16 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Kuros Biosciences's current Enterprise Value is CHF370.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-10.41 Mil.
Kuros Biosciences's current Enterprise Value is CHF370.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF33.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Kuros Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Kuros Biosciences (XSWX:KURN) Business Description
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:KURN has been successfully added to your 